Cardiovascular (CV) and lifestyle associated risk factors (RFs) are increasingly recognized as important for Alzheimer's disease (AD) pathogenesis. Beyond the ε 4 allele of apolipoprotein E (APOE), comparatively little is known about whether CV associated genes also increase risk for AD (genetic pleiotropy). Using large genome-wide association studies (GWASs) (total n > 500,000 cases and controls) and validated tools to quantify genetic pleiotropy, we systematically identified single nucleotide polymorphisms (SNPs) jointly associated with AD and one or more CV RFs, namely body mass index (BMI), type 2 diabetes (T2D), coronary artery disease (CAD), waist hip ratio (WHR), total cholesterol (TC), lowdensity (LDL) and high-density lipoprotein (HDL). In fold enrichment plots, we observed robust genetic enrichment in AD as a function of plasma lipids (TC, LDL, and HDL); we found minimal AD genetic enrichment conditional on BMI, T2D, CAD, and WHR. Beyond APOE, at conjunction FDR < 0.05 we identified 57 SNPs on 19 different chromosomes that were jointly associated with AD and CV outcomes including APOA4, ABCA1, ABCG5, LIPG, and MTCH2/SPI1. We found that common genetic variants influencing AD are associated with multiple CV RFs, at times with a different directionality of effect. Expression of these AD/CV pleiotropic genes was enriched for lipid metabolism processes, over-represented within astrocytes and vascular structures, highly co-expressed, and differentially altered within AD brains. Beyond APOE, we show that the polygenic component of AD is enriched for lipid associated RFs. Rather than a single causal link between genetic loci, RF and the outcome, we found that common genetic variants influencing AD are associated with multiple CV RFs. Our collective findings suggest that a network of genes involved in lipid biology also influence Alzheimer's risk.
INTRODUCTION
There is mounting evidence that cardiovascular (CV) disease impacts Alzheimer's disease (AD) pathogenesis. Co-occurrence of CV and AD pathology is the most common cause of dementia among the elderly [4] and imaging manifestations of vascular disease are routinely observed on MRI scans of AD patients [36] . Observational epidemiology studies have found that cardiovascular/lifestyle related risk factors (RFs) are associated with dementia risk and targeting these modifiable RFs may represent a viable dementia prevention strategy [5, 26] . Recently, the National Academy of Medicine [24] and the Lancet [19] commissioned independent reports on strategies for dementia prevention. Both reports found encouraging evidence for targeting cardiovascular RFs with the Lancet commission concluding that 35% of dementia could be prevented by modifying several RFs including diabetes, hypertension, obesity, and physical inactivity.
Genetic studies have found CV associated loci that also increase risk for late-onset AD.
The ε 4 allele of apolipoprotein E (APOE) is the biggest genetic risk factor for AD and encodes a lipid transport protein involved in cholesterol metabolism [22] . Genome-wide association studies (GWAS) in late-onset AD have identified single nucleotide polymorphisms (SNPs) implicated in lipid processes, such as CLU and ABCA7 [17, 31] , and enrichment in cholesterol metabolism pathways [7] . Considered together, these findings suggest 'pleiotropy', where variations in a single gene can affect multiple, seemingly unrelated phenotypes [37] .
We have previously shown that genetic enrichment in CV traits/diseases (hereafter referred to as RFs) results in improved statistical power for discovery of novel AD genes [10] .
Building on this work, in the present study, we systematically evaluated shared genetic risk between AD and cardiovascular/lifestyle associated RFs and diseases. We focused on publicly available genetic data from cardiovascular outcomes and a combination of traits and diseases that have been epidemiologically associated with increased AD risk. Using large GWAS and validated tools to estimate pleiotropy, we sought to identify SNPs jointly associated with AD and one or more CV RFs, namely body mass index (BMI), type 2 diabetes (T2D), coronary artery disease (CAD), waist hip ratio (WHR), total cholesterol (TC), low-density (LDL), and highdensity lipoprotein (HDL). Using large publicly available databases, we additionally examined whether the AD/CV pleiotropic genes are enriched for biological processes, over-represented within specific tissue and cell types, co-expressed, and differentially expressed within AD brains.
METHODS

Participant samples
We evaluated complete GWAS results in the form of summary statistics (p-values and odds ratios) for clinically diagnosed AD dementia and seven CV associated RFs, including BMI [20] , T2D [32] , CAD [25] , WHR [33] , and plasma lipid levels (TC, LDL, and HDL [ 42] ; Table   1 ). We obtained publicly available AD GWAS summary statistic data from the International Genomics of Alzheimer's Disease Project (IGAP Stage 1, for additional details see Supplemental Information and [17] ; Table 1 ). The IGAP Stage 1 consists of 17,008 AD cases (mean age = 74.7 ± 7.7 years; 59.4% female) and 37,154 controls (mean age = 76.3 ± 8.1 years; 58.6% female) drawn from four different consortia across North America and Europe with genotyped or imputed data at 7,055,881 SNPs (for a description of the AD dementia cases and controls within the IGAP Stage 1 sub-studies, please see [17] ).
We obtained publicly available BMI GWAS summary statistic data from the Genetic Investigation of Anthropometric Traits consortium (GIANT, for additional details see [20] ; Table 1 ). The BMI GWAS meta-analysis consists of 339,224 individuals of European and nonEuropean descent from 125 studies. The meta-analysis summary statistics were adjusted for age, sex and inverse normal transformation of the residuals.
The publicly available T2D GWAS summary statistic data were obtained from the Diabetes Genetics Replication and Meta-analysis consortium (DIAGRAM, for additional details see [32] ; Table 1 ). The T2D GWAS meta-analysis Stage 1 summary statistics were drawn from 18 studies and consists of 26,676, T2D cases and 132,532 controls from European and nonEuropean decent. Stage 1 summary statistics were adjusted for age, sex and principal components derived from the genetic data to account for population stratification. Genomic control (GC) correction to study-level was also conducted to correct for residual population structure not accounted for by principal components adjustment.
We obtained publicly available CAD GWAS summary statistic data from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics). The CARDIoGRAMplusC4D 1000 Genomes-based GWAS meta-analysis consists of 60,801 CAD cases and 123,504 controls from European and non-European decent (for additional details see [25] ; Table 1 ). The meta-analysis statistics were adjusted for over-dispersion.
We obtained publicly available WHR without adjustment for BMI GWAS summary statistic data from the GIANT consortium (for additional details see [33] ; Table 1 ). The WHR GWAS meta-analysis summary statistics included 224,459 individuals of European and nonEuropean decent. The summary statistics were adjusted for age and study-specific covariates.
Residuals were calculated for men and women separately and then transformed by the inverse standard normal function.
Lastly, we obtained publicly available TC, LDL, and HDL GWAS summary statistic data from Global Lipids Genetics Consortium (for additional details see [42] ; Table 1 ). The TC, LDL, and HDL GWAS summary statistics included 188,577 individuals of European and nonEuropean decent. The summary statistics were adjusted for age and sex.
The relevant institutional review boards or ethics committees approved the research protocol of all individual GWAS used in the current analysis, and all human participants gave written informed consent.
Genetic Enrichment and Conjunction False Discovery Rates (FDR)
We evaluated whether there is pleiotropic enrichment in AD as a function of each of the seven CV RFs (see Supplemental Information). These validated methods have been described previously [2, 3, 6, 16, 44] . Briefly, for given associated phenotypes A (e.g. AD) and B (e.g. BMI), pleiotropic 'enrichment' of phenotype A with phenotype B exists if the proportion of SNPs or genes associated with phenotype A increases as a function of increased association with phenotype B. To assess for enrichment, we constructed fold-enrichment plots of nominallog 10 (p) values for all AD SNPs and for subsets of SNPs determined by the significance of their association with each of the seven CV RFs. In fold-enrichment plots, the presence of enrichment is reflected as an upward deflection of the curve for phenotype A if the degree of deflection from the expected null line is dependent on the degree of association with phenotype B. To assess for polygenic effects below the standard GWAS significance threshold, we focused the foldenrichment plots on SNPs with nominal -log 10 (p) < 7.3 (corresponding to p > 5x10 -8 microtubule-associated tau protein (MAPT) region on chromosome 17 [9] and the APOE region on chromosome 19 [10] are associated with increased AD risk, one concern is that random pruning may not sufficiently account for these large LD blocks resulting in artificially inflated genetic enrichment [6] . To better account for these large LD blocks, in our genetic enrichment analyses, we removed all SNPs in LD with r 2 > 0.2 within 1Mb of HLA, MAPT and APOE variants (based on 1000 Genomes Project LD structure).
To identify specific loci jointly involved with AD and the seven CV RFs, we computed conjunction FDRs, as previously described [2, 3, 6, 43, 44] . Briefly, conjunction FDR, denoted by FDR trait1& trait2 is defined as the posterior probability that a SNP is null for either trait or for both simultaneously, given the p-values for both traits are as small, or smaller, than the observed p-values. Unlike the conditional FDR which ranks disease/primary phenotype associated SNPs based on genetic 'relatedness' with secondary phenotypes, the conjunction FDR minimizes the possibility/likelihood of a single phenotype driving the common association signal. Conjunction FDR therefore is more conservative and specifically pinpoints pleiotropic loci between the traits of interest. We used an overall FDR threshold of < 0.05, which means 5 expected false discoveries per hundred reported. Manhattan plots were constructed based on the ranking of conjunction FDR to illustrate the genomic location of the pleiotropic loci. In all analyses, we controlled for the effects of genomic inflation by using intergenic SNPs (see Supplemental Information). Detailed information on fold enrichment plots, Manhattan plots, and conjunction FDR can be found in Supplemental Information and prior reports [2, 3, 6, 43, 44] .
Functional evaluation of shared risk loci
To assess whether SNPs that are shared between AD and CV RFs modify gene expression, we identified cis-expression quantitative loci (eQTLs, defined as variants within 1
Mb of a gene's transcription start site) and regional brain expression of AD/CV SNPs in a publicly available dataset of normal control brains (UKBEC, http://braineac.org [30] ). Given the evaluation of CV RFs, we also evaluated eQTLs using a blood-based dataset [41] , We applied an analysis of covariance (ANCOVA) to test for associations between genotypes and gene expression. We tested SNPs using an additive model.
Functional association analyses
To evaluate enrichment in tissue types and biological pathways of the AD/CV pleiotropic genes, we used FUMA, a web-based platform that integrates information from multiple biological resources to facilitate functional annotation of GWAS results [40] . To evaluate potential protein and genetic interactions, co-expression, co-localization and protein domain similarity between the overlapping genes, we used GeneMANIA, (http://genemania.org), an online web-portal for bioinformatic assessment of gene networks [39] .
Gene expression alterations in AD brains
To determine whether the AD/CV pleiotropic genes are differentially expressed in AD 
RESULTS
Pleiotropic enrichment in AD conditional on plasma lipid levels
For progressively stringent p-value thresholds for AD SNPs (i.e. increasing values of nominal -log 10 (p)), we found at least 40-fold enrichment using TC, 20-fold enrichment using HDL and 60-fold enrichment using LDL (Figure 1 ). In comparison, we found no enrichment with BMI, T2D, CAD, and WHR. We note that these results reflect genetic enrichment in AD as a function of CV RFs after the exclusion of SNPs in LD with HLA, MAPT, and APOE (see Methods).
Given the long-range LD associated with the APOE/TOMM40 region [45] , we focused our pleiotropy analyses on genetic variants outside chromosome 19. At a conjunction FDR < 0.05, we identified 57 SNPs, in total, across 19 chromosomes jointly associated with AD and CV RFs ( Figure 2 , Table 2 ). Of these, we found that on chromosome 11, rs11039149 (closest gene = 
Shared genetic risk between CV RFs
To evaluate whether the AD susceptibility loci listed in Table 2 are associated with a single CV RF or with multiple associated RFs, we constructed a matrix plot. For each of the 7 CV RFs, we plotted the magnitude and direction of associated z-scores for all 57 AD/CV SNPs/closest genes ( Figure 3 , Supplemental Table 1 ). We found that many of the AD/CV SNPs/closest genes were associated with multiple CV RFs and with different direction of effects.
For example, a) rs1883025/ABCA1 was associated with a z-score of -6.82 with LDL (p-value of 
cis-eQTLs
We found significant cis-associations between the AD/CV pleiotropic SNPs and 173 genes in either brain or blood tissue types (Supplemental Table 2 region, we found a cis-association between rs3852860 and PVRL2 that was significant in both brain and blood suggesting AD/CV pleiotropic genetic signal on chromosome 19 that is independent from APOE.
Gene ontology and gene-protein network analyses
At an FDR < 0.05, we found that the closest genes associated with the AD/CV polymorphisms were associated with multiple gene ontology (GO) molecular, cellular, and biological pathways and tissue types. These shared loci were highly enriched for lipid-associated processes including cholesterol and sterol transport, regulation, binding, and activity (Supplemental Figure 2 ). Beyond APOE, several genes were associated with lipid metabolism including ABCA1, ATP8B4, APOA4, ABCG5, ITGB3, LIPG, and NR1H3. We also found that expression of the AD/CV pleiotropic genes was over-represented within different tissue types, in particular the cerebral cortex, skin, subcutaneous fat and arterial structures including the coronary artery (Supplemental Figure 3a) . Beyond APOE, several genes were highly expressed across a number of tissue types including C1S, PSMC3, PTK2B, RAC1, and RPL6 (Supplemental Figure 3b ). In our 'network' analysis, we found that the majority of the AD/CV pleiotropic genes were co-expressed (53%), co-localized (13%), or showed shared protein domains (10%) ( Figure   4 ). Functional analyses across functionally expressed AD/CV pleiotropic genes (i.e. those with significant cis-eQTLs in both brain and blood) are shown in Supplemental Figures 4-6 .
Gene expression in brains from AD patients and healthy controls
To investigate whether the AD/CV pleiotropic genes are differentially expressed in AD brains, we compared gene expression in AD brains with neuropathologically normal control brains. For several shared AD/CV genes, we observed differential expression in AD brains compared to controls (Supplemental Table 3 ). We found the strongest effects (absolute magnitude of beta-coefficients) for differential expression of CDC73, TRPS1, ABCA1, USP24, and ABCG5 ( Figure 5 ). Similarly, across functionally expressed pleiotropic genes (i.e. those with significant cis-eQTLs in both brain and blood), we observed differential expression in AD brains ( Figure 5 , Supplemental Table 4 ).
Cell type enrichment
Across different central nervous system cell types, we found that the AD/CV pleiotropic genes were highly expressed in astrocytes ( Figure 6 ). Similarly, across functionally expressed pleiotropic genes (i.e. those with significant cis-associations in both brain and blood), we found enrichment in astrocytes and microglia/macrophages ( Figure 6 ). Notable examples include ABCA1 (astrocytes), MTCH2 (astrocytes), and SPI1 (microglia/macrophages) (Supplemental Figures 7-8) .
DISCUSSION
Beyond APOE, we identified 57 SNPs on 19 different chromosomes that jointly conferred increased risk for AD and cardiovascular outcomes. Expression of these AD/CV pleiotropic genes was enriched for lipid and cholesterol metabolism processes, over-represented within the CNS (mainly astrocytes) and vascular structures, highly co-expressed, and differentially altered within AD brains. Collectively, our findings suggest that the polygenic component of AD is highly enriched for lipid associated RFs.
In their genetic association with AD, not all cardiovascular RFs are created equal. We found minimal genetic enrichment in AD as a function of T2D, BMI, WHR, and CAD suggesting that the known comorbidity [21, 28, 35] between these CV RFs and Alzheimer's etiology is likely not genetic. In contrast, genetic enrichment in AD was predominantly localized to plasma lipids. Building on our prior work leveraging statistical power from large CV GWASs for AD gene discovery [10] , we found genetic variants jointly associated with AD and CV RFs, many with known cholesterol/lipid function. By conditioning on plasma TC, LDL, and HDL levels, we identified AD susceptibility loci within genes encoding apolipoproteins, such as APOA4, ATP-binding cassette transporters, such as ABCA1 and ABCG5, and phospholipases, such as ATP8B4 and LIPG (for a discussion on lipid genes and AD see [11] ). In functional analyses, expression of these pleiotropic genes was enriched for lipid metabolism pathways, over-represented within the brain and arteries, and perturbed within the brains of AD patients.
Considered together with our co-expression findings, these results are consistent with the hypothesis that a network of non-APOE genes implicated in lipid biology also influence Alzheimer's pathobiology.
Our pleiotropy findings suggest that complex diseases and traits have a complex genetic architecture. Although we did not evaluate causal associations using a Mendelian Randomization (MR) framework, our results have implications for the relationship between common genetic variants, cardiovascular RFs and AD as an outcome. To date, MR studies have typically evaluated a single CV risk factor at a time, which is valid only if the genetic variants used for the MR influence AD exclusively via the selected CV risk factor [18, 27] . For a number of variants, we found pleiotropy challenging the conventional MR approach (for a review on the assumptions underlying MR see [12] ); that is, common genetic variants influencing AD are associated with multiple CV RFs, at times with a different directionality of effect ( Figure 3 , Supplemental Table   2 ). Instead of a single causal link between genetic variants, RF and the outcome [13] , these results suggest two possible scenarios: 1. genetic variants influence cardiovascular RFs and AD independently, or, 2. genetic variants influence AD through multiple cardiovascular RFs.
On chromosome 11, our pleiotropy and eQTL results point to AD associated genetic signal within MTCH2 and SPI1, independent from CELF1/CUGB1. By conditioning on cardiovascular RFs, we identified several SNPs tagging variants within NR1H3, MTCH2, MYBPC3 and CELF1. The eQTL analyses showed cis-associations with MTCH2 and SPI1, both of which showed differential gene expression alterations in AD brains. Consistent with our findings, a recent study found an AD risk locus within the CELF1 region that was associated with lower expression of SPI1 in monocytes and macrophages [14, 15] . SPI1 encodes a transcription factor, PU.1, that is essential for myeloid cell development and a major regulator of cellular communication in the immune system [23] . We note that the majority of our pleiotropic genes were expressed in astrocytes and to a lesser extent, microglia, implicating genes expressed in microglia, astrocytes or other myeloid cell types in AD pathogenesis [34] .
Our findings have clinical implications. First, given the common co-occurrence of vascular and Alzheimer's pathology, it is highly likely that the clinically diagnosed AD individuals from our cohort have concomitant vascular brain disease, which may further contribute to their cognitive decline and dementia. As such, a plausible interpretation of our findings is that the susceptibility loci identified in this study may increase brain vulnerability to vascular and/or inflammatory insults, which in turn may exacerbate the clinical consequences of AD pathological changes. Second, no single common variant detected in this study will be clinically informative. Rather, integration of these pleiotropic variants into a cardiovascular pathway specific, polygenic 'hazard' framework for predicting AD age of onset may help identify older individuals jointly at risk for cardiovascular and Alzheimer's disease [8] .
Therapeutically targeting cardiovascular RFs in these individuals may impact the Alzheimer's disease trajectory.
This study has limitations. First, whereas several of the CV RF GWASs included European and non-European ancestry individuals, the IGAP AD cohort restricted analyses to non-Hispanic Whites. Therefore, these results may not be generalizable to AD patients from other populations. Second, our AD patients were diagnosed largely using clinical criteria without neuropathology confirmation and this may result in misclassification of case status. However, such misclassification should reduce statistical power and bias results toward the null. Finally, given evidence that phospholipids are proinflammatory [29] , future work should evaluate whether LDL, HDL or TC influence AD risk through inflammation or other mediator variables.
In summary, across a large cohort (n > 500,000 cases and controls), we show cardiovascular associated polygenic enrichment in AD. Table 2 and Fig. 2 ) Fig. 4 Network interaction graph predominantly illustrating co-expressed (purple), co-localized (blue), and shared protein domains (khaki) for AD/CV pleiotropic genes 
